Work Area: Valuation

Latest content

Australia under-invests in IP, and recent government proposals will not fix that

Saturday Opinion: In-house leaders say a mooted patent box regime limited to life sciences will reward companies that get patents already, failing to encourage IP investment in new industries

04 December 2021

Why patent litigators are now central to a wide range of commercial disputes

The Long Read: It’s no longer all about infringement, write Michelle Avery, Nicole McTernan and Drew Sills of Ocean Tomo. Instead, IP specialists are increasingly being called on in a diverse array of corporate lawsuits

01 December 2021

Data monetisation drives Sanofi’s $180 million investment in AI biotech Owkin

The deal shows how privacy and silo barriers to the commercialisation of information are being overcome

29 November 2021

The IP story to engage the c-suite is there, but it takes bravery to tell it

Saturday Opinion: After a highly successful IPBC in Seattle earlier this week, it is clear that there has never been a better time to take the value creation gospel to the boardroom

20 November 2021

How Aon helps lenders and borrowers manage risk in IP-backed deals

Brian Hinman, chief commercial officer at Aon IP Solutions, tells IAM how the group facilitates IP-backed funding deals centred on high-quality assets

18 November 2021

A $650 million deal is the latest in a growing number of CRISPR IP transactions

Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum

05 November 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales

01 November 2021

Nokia Technologies boosts revenues and profits in strong Q3 patent licensing performance

Royalties grow on the back of new deals and renewals; company also shares new details on legal fight with Oppo, which does not appear to have significantly dimmed income outlook

29 October 2021

Hub and spoke IP strategies are generating billions of dollars in biopharma

New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets

22 October 2021

Get unlimited access to all IAM content